ArticleCureus2024
Isatuximab for Stem Cell Transplant-Ineligible Multiple Myeloma: An Editorial.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trials.Annals of hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent approval of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (Isa-VRd) marks a significant advancement in the treatment of stem cell transplant-ineligible multiple myeloma (MM) patients. MM, the second most common hematological malignancy globally, poses substantial challenges, especially for patients who are unable to undergo autologous stem cell transplantation due to advanced age or comorbidities. Isatuximab, a CD38-targeting monoclonal antibody, has demonstrated promising efficacy in the pivotal trial, which reported a 40% reduction in disease progression or death for patients treated with Isa-VRd compared to bortezomib-lenalidomide-dexamethasone alone. The trial also showed higher rates of complete response and minimal residual disease (MRD)-negative status in the Isa-VRd group without introducing new safety concerns. These findings suggest that isatuximab's integration into first-line therapy could substantially improve long-term outcomes for this underserved patient population. Clinicians are encouraged to adopt regular MRD monitoring and provide comprehensive patient education on potential side effects to optimize treatment adherence. Further research on isatuximab's use in combination with other emerging therapies may continue to expand therapeutic possibilities, offering hope for more effective management of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.